China-based Shanghai Henlius Biotech Inc (2696.HK) and Accord Healthcare Limited, a subsidiary of Intas Pharmaceuticals Ltd, have received approval from the European Commission (EC) for their Zercepac, a biosimilar, trastuzumab, intended for the treatment of certain patients with HER2-positive early breast cancer, HER2-positive metastatic breast cancer and earlier untreated HER2-positive metastatic gastric cancer, it was reported on Wednesday.
The product received approval based on a series of studies including comparative quality studies, preclinical and clinical studies.
Zercepac was developed and produced by Henlius and is the first monoclonal antibody (mAb) and third biosimilar, launched by Accord in Europe, and is the first mAb developed by Henlius to be approved in the European Union.
Sanofi receives FDA orphan drug designation for riliprubart in transplant rejection
Hoth Therapeutics reports positive interim results for HT-001 topical therapy
Breckenridge Pharmaceutical's generic for Ablysinol granted final FDA approval
Hemab Therapeutics presents bleeding disorder clinical and preclinical data at ISTH 2025 Congress
Cumberland Pharmaceuticals reports ifetroban Phase 2 DMD heart disease trial results
Sarclisa recommended for EU approval in newly diagnosed transplant-eligible multiple myeloma
FDA approves Dupixent as first targeted therapy for rare skin disease bullous pemphigoid